The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Satellite Symposium | Patient with R/R DLBCL—US perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub was proud to host a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma. Kieron Dunleavy, George Washington University Cancer Center, Washington, US, summarizes what he considers to be the feasible next steps for a patient with diffuse large B-cell lymphoma (DLBCL) following relapse to chimeric antigen receptor (CAR) T-cell therapy.

Satellite Symposium | Patient with R/R DLBCL— US perspective

He outlines recently approved agents and combination regimens, as well as therapies being evaluated in clinical trials. Kieron Dunleavy concludes with an emphasis on prognostic techniques, stressing the need for a biopsy to determine the patients CD19 expression profile. In terms of therapeutic approach, he suggests enrolling the patient onto a clinical trial evaluating novel bispecific antibodies.

Satellite Symposium | Patient with R/R DLBCL— US perspective

If you would like to download the slides from Kieron Dunleavy's presentation, click below.

Download here

Share: